Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

Exclusion Criteria18

• Patients who have had or currently have other malignant tumors within the past five years.
• Presence of brain metastasis.
• History of clinically significant central nervous system disorders, either in the past or at screening.
• Imaging indicating tumor invasion of major blood vessels or indistinct borders with blood vessels.
• Individuals who have received cytotoxic drugs or other interventions, assessed by the investigator as potentially impacting lymphocyte expansion, within 14 days or at least five half-lives (whichever is shorter) prior to blood collection for CAR-T preparation.
• Presence of other viremias.
• History of severe allergies.
• Patients with severe cardiac disease.
• Patients with severe hepatic and renal dysfunction or disorders of consciousness.
• Patients with active autoimmune or inflammatory diseases.
• Patients with objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonia, severe lung function impairment, etc.
• Patients who have undergone or are awaiting organ transplantation.
• Infections requiring intravenous antibiotic therapy for control or are uncontrollable.
• Individuals who have received live (attenuated) virus vaccines within four weeks prior to screening.
• Alcoholics or individuals with a history of substance abuse.
• Pregnant or lactating women.
• Individuals who have participated in other clinical trials involving drugs within the past 30 days.
• Patients who, based on the investigator's judgment and/or clinical standards, have contraindications to any study procedures or present other medical conditions that may pose unacceptable risks.